The company develops a gene therapy focused on neurodegenerative diseases. Its headquarters are in State College, PA, and Shanghai, China. With this round of funding, the company also announced that it has added two members to its board of directors: Dr. Xin Huang and Jonathan Sun.

The company has developed a neural repair technology through astrocyte-to-neuron conversion in vivo by introducing neural transcription factor(s) through adeno-associated virus-based gene therapy. NeuExcell's pipeline covers major neurodegenerative diseases such as stroke, Huntington's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, traumatic brain injury, spinal cord injury, and glioma.

Next-generation gene therapy points to base editing
Base editing has emerged as a new player in the gene therapy arena, with rapid advances in technology and evidence of proof of concept in rare genetic...

Cell and gene therapy firms see over $13.6B so far in 2021
Rapid financing activity in the cell and gene therapy industry has exceeded $13 billion in 2021. Over half of this funding is from venture capital and...

Alternative gene therapies could be effective in treating some rare diseases
Bacteria-mediated genetic transfer has emerged as an alternative gene therapy (AGT) for the treatment of some rare diseases, such as phenylketonuria (PKU)....

Scientists visualize viruses in motion using advanced electron microscopy
Advanced electron microscopy has enabled researchers to visualize how human viruses move in high resolution in a near-native environment. The visualization...

Cellular programming spurs next-generation cell therapies
Cellular reprogramming of ex vivo cells may offer improvements on first-generation adoptive cell therapies, which have experienced limited clinical success...